NKMAX Co., Ltd. Logo

NKMAX Co., Ltd.

Biotech firm for NK cell therapies, global research reagents, diagnostics, and supplements.

182400 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 돌마로 172 정자동, 헬스케어혁신파크 1층및6층, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NKMAX Co., Ltd. is a biotechnology company specializing in technologies centered on Natural Killer (NK) cells. The company's operations span multiple segments, including the development of NK cell-based immunotherapies for cancer and other diseases. It is a key global manufacturer and supplier of high-quality research reagents, providing recombinant proteins and monoclonal antibodies to over 2,000 research institutions and diagnostic firms worldwide. Additionally, NKMAX offers a precision diagnostic test to quantify NK cell activity for immune function assessment and markets a line of dietary supplements, such as NK365, designed to support the immune system.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for NKMAX Co., Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-04 00:00
Legal Proceedings Report
회생절차종결결정
Korean 8.5 KB
2025-09-03 00:00
Regulatory News Service
기타시장안내 (실질심사 대상여부 결정을 위한 조사기간 연장 안내 )
Korean 3.2 KB
2025-08-25 00:00
Legal Proceedings Report
회생절차종결신청
Korean 12.4 KB
2025-08-14 00:00
Board/Management Information
대표이사변경
Korean 10.4 KB
2025-08-14 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 13.7 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-08-14 00:00
Audit Report / Information
반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Korean 13.6 KB
2025-08-13 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 대상결정 기한 안내)
Korean 3.1 KB

Automate Your Workflow. Get a real-time feed of all NKMAX Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for NKMAX Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
REYON PHARMACEUTICAL CO., LTD Logo
Develops & makes APIs, generics, cell/gene therapies, and offers biopharma CDMO services.
South Korea 102460
Roche Holding AG Logo
A global leader in pharmaceuticals and diagnostics, pioneering personalized healthcare solutions.
Switzerland RO
ROHTO PHARMACEUTICAL CO.,LTD. Logo
Manufactures OTC drugs, skincare, and cosmetics with a focus on eye and dermatological health.
Japan 4527
RPbio Inc. Logo
A global CDMO specializing in soft capsules, pharmaceuticals, and health functional foods.
South Korea 314140
Develops and produces IVD kits and biological pharmaceuticals for the healthcare sector.
Türkiye RTALB
SAMIL PHARMACEUTICAL CO.,LTD Logo
Develops & manufactures drugs for eye & liver diseases, with a broad portfolio & CDMO services.
South Korea 000520
SAMJIN PHARMACEUTICAL CO.,LTD Logo
Researches & develops drugs for cardiovascular, respiratory, and gastrointestinal disorders.
South Korea 005500
SAMSUNG BIOLOGICS CO.,LTD. Logo
A CDMO providing end-to-end development and manufacturing services for the biopharma industry.
South Korea 207940
SanBio Company Limited Logo
Developing regenerative cell therapies for severe neurological disorders like brain injury and stroke.
Japan 4592
SANIGEN Co., Ltd. Logo
Provides food safety solutions and genetic diagnostics for the entire food industry.
South Korea 188260

Talk to a Data Expert

Have a question? We'll get back to you promptly.